DPX-101 / Damona Pharmaceuticals - LARVOL DELTA

Damona Announces Publication of Preclinical Proof-of-Concept Data for DPX-101 (GL-II-73) Demonstrating Symptomatic and Disease-Modifying Potential for the Treatment of Cognitive Deficits in Alzheimer’s Disease (PRNewswire) - "Damona Pharmaceuticals...announced today the publication of data demonstrating that DPX-101 reverses cognitive deficits induced by amyloid deposition in a widely used preclinical model of Alzheimer's disease. The publication...will be published in the March 2025 issue of Neurobiology of Aging....Acute administration of DPX-101 prevented spatial working memory deficits at 2 months of age. Chronic administration of DPX-101 reversed spatial working memory deficits at 5 months of age. Chronic administration of DPX-101 prevented pyramidal cell atrophy....Company plans to initiate Phase 1 clinical trial in first half of 2025."

New P1 trial • Preclinical • Alzheimer's Disease • Cognitive Disorders

Damona Announces Publication of Preclinical Proof-of-Concept Data for DPX-101 (GL-II-73) Demonstrating Symptomatic and Disease-Modifying Potential for the Treatment of Cognitive Deficits in Alzheimer’s Disease (PRNewswire) - "Company plans to initiate Phase 1 clinical trial in first half of 2025...Damona Pharmaceuticals...announced today the publication of data demonstrating that DPX-101 reverses cognitive deficits induced by amyloid deposition in a widely used preclinical model of Alzheimer's disease...Summary and key findings....Acute administration of DPX-101 prevented spatial working memory deficits at 2 months of age; Chronic administration of DPX-101 reversed spatial working memory deficits at 5 months of age; Chronic administration of DPX-101 prevented pyramidal cell atrophy; Chronic administration of DPX-101 preserved pyramidal cell spine density, spine count, and dendritic length at early and late time points, despite ongoing β-amyloid accumulation; The cognitive and neurotropic effects of DPX-101 occurred independent of β-amyloid buildup."

New P1 trial • Preclinical • Alzheimer's Disease